
Opinion|Videos|March 30, 2026
Interpreting Overall Survival Data With Combination Strategies in EGFR-Mutant NSCLC
Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, examine how overall survival data from recent trials are influencing treatment decisions.
Advertisement
Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, discuss how results from FLAURA2 (NCT04035486) and MARIPOSA (NCT04487080) have introduced meaningful overall survival benefits with intensified approaches. They consider patient age, comorbidities, renal function, lifestyle factors, and treatment logistics. They also discuss the importance of disease burden and central nervous system involvement, while acknowledging the potential risk of overtreatment and the need to balance efficacy, toxicity, and long-term sequencing flexibility.
Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
5

